Association between interleukin-6 promoter polymorphism (-174 G/C), serum interleukin-6 levels and mortality in severe septic patients

The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053-0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074-1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days

The 4G/4G genotype of PAI-1 polymorphism is associated with higher plasma PAI-1 concentrations and mortality in patients with severe sepsis

Objective: Two studies have reported that patients with the 4G/4G genotype of the plasminogen activator inhibitor-1 (PAI-1) genetic polymorphism had higher plasma PAI-1 concentrations and higher risk of death than those with the 4G/5G or 5G/5G genotypes; one study involved 175 children with meningococcal disease, and the other included 88 adult patients with septic shock. Thus, the objective of this study was to determine whether there is an association between carriage of the 4G/4G genotype, plasma PAI-1 concentrations and mortality in a large series of adult septic patients. Methods: An observational, prospective, multicenter study was carried out in six Spanish Intensive Care Units including severe septic patients. We determined the PAI-1 4G/5G polymorphism and plasma PAI-1 concentrations in all patients. The end-points of the study were 30-day and 6-month mortality. Results: We included a total of 260 patients, 82 (31.5%) with 4G/4G, 126 (48.5%) with 4G/5G and 52 (20.0%) with 5G/5G genotype. Multivariate logistic regression analysis showed that the 4G/4G genotype was associated with higher mortality at 30 days (Odds Ratio = 1.95; 95% CI = 1.063-3.561; p = 0.03) and at 6 months (Odds Ratio = 2.19; 95% CI = 1.221-3.934; p = 0.01), and that higher plasma PAI-1 concentrations were associated with higher mortality at 30 days (Odds Ratio = 1.01; 95% CI = 1.002-1.022; p = 0.02) at 6 months (Odds Ratio = 1.01; 95% CI = 1.003-1.023; p = 0.01). Multivariate linear regression analysis showed that increased plasma PAI-1 concentrations were associated with the PAI-1 4G/4G genotype (regression coefficient = 4.82; 95% CI = 3.227 to 6.406; p<0.001). Conclusions: The major findings of our study, to our knowledge the largest series reporting data about 4G/5G polymorphism of the PAI-1 gene, plasma PAI-1 concentrations and mortality in septic patients, were that septic patients with the 4G/4G genotype had higher plasma PAI-1 concentrations and higher risk of death than those with 4G/5G or 5G/5G genotypes

Sustained high serum caspase-3 concentrations and mortality in septic patients

Caspase-3 is the main executor of the apoptotic process. Higher serum caspase-3 concentrations in non-survivor compared to survivor septic patients have been found. The objectives of this work (with the increase of sample size to 308 patients, and the determination of serum caspase-3 concentrations also on days 4 and 8 of diagnosis of severe sepsis) were to know whether an association between serum caspase-3 concentrationss during the first week, degree of apoptosis, sepsis severity, and sepsis mortality exists. We collected serum samples of 308 patients with severe sepsis from eight intensive care units on days 1, 4 and 8 to measure concentrations of caspase-3 and caspase-cleaved cytokeratin (CCCK)-18 (to assess degree of apoptosis). End point was 30-day mortality. We found higher serum concentrations of caspase-3 and CCCK-18 in non-survivors compared to survivors on days 1 (p < 0.001), 4 (p < 0.001), and 8 (p < 0.001). We found an association between serum caspase-3 concentrations on days 1, 4 and 8 of severe sepsis diagnosis and serum CCCK-18 concentrations (p < 0.001), SOFA (p < 0.001), serum acid lactic concentrations (p < 0.001), and 30-day sepsis mortality (p < 0.001). The new findings of this work were that an association between serum caspase-3 concentrations during the first week, apoptosis degree, sepsis severity, and sepsis mortality exists

Serum melatonin levels during the first seven days of severe sepsis diagnosis are associated with sepsis severity and mortality

Objective: Higher serum melatonin levels have previously been found in patients with severe sepsis who died within 30 days of diagnosis than in survivors. The objective of our study were to determine whether serum melatonin levels during the first seven days of severe sepsis diagnosis could be associated with sepsis severity and mortality. Methods: Multicentre study in eight Spanish Intensive Care Units which enrolled 308 patients with severe sepsis. We determined serum levels of melatonin, malondialdehyde (as biomarker of lipid peroxidation) and tumor necrosis factor-alpha at days 1, 4 and 8 of severe sepsis diagnosis. The study's primary endpoint was 30-day mortality. Results: A total of 103 patients had died and 205 survived at 30 days of severe sepsis diagnosis, with the non-survivors presenting higher serum melatonin levels at days 1 (p<0.001), 4 (p<0.001) and 8 (p<0.001) of severe sepsis diagnosis than the survivor patient group. The multiple logistic regression analysis found that serum melatonin levels at days 1, 4 and 8 of severe sepsis diagnosis (p<0.001, p = 0.01 and p = 0.001, respectively) were associated with mortality adjusted for age, serum lactic acid, SOFA score and diabetes mellitus. Conclusions: The novel and more interesting findings of our study were that serum melatonin levels during the first seven days of severe sepsis diagnosis are associated with sepsis severity and mortality. (C) 2017 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades lnfecciosas y Microbiologia Clinica

High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

Background: Higher circulating levels of tissue inhibitor of matrix metalloproteinases (TIMP)-1 early after ischemic stroke have been associated with lower survival. The objectives of this study were to determine serum TIMP-1 levels during the first week of a severe cerebral infarction in surviving and non-surviving patients, and whether those levels during the first week could be used as a mortality biomarker for these patients. Methods: We included patients with severe malignant middle cerebral artery infarction (MMCAI) defined as computer tomography showing ischaemic changes in more than 50% of the middle cerebral artery territory and Glasgow Coma Scale (GCS) ≤ 8. We measured serum levels of matrix metalloproteinases (MMP)-9 and TIMP-1. End-point study was 30-day mortality. Results: We found higher TIMP-1 concentrations at days 1 (p < 0.001), 4 (p = 0.001), and 8 (p = 0.03) of MMCAI in nonurviving (n = 34) than in surviving (n = 34) patients. We found lower serum MMP-9 concentrations at day 1 (p = 0.03) of MMCAI and no significant differences at days 4 and 8. ROC curve analysis of TIMP-1 concentrations performed at days 1, 4, and 8 of MMCAI showed an area under curve to predict 30-day mortality of 81% (p < 0.001), 80% (p < 0.001) and 72% (p = 0.07) respectively. Conclusions: The new findings of our study were that non-surviving MMCAI patients showed higher serum TIMP-1 levels during the first week of MMCAI that surviving patients, and those levels during the first week of MMCAI could be used as mortality biomarkers

Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

INTRODUCTION: CD40 Ligand (CD40L) and its soluble counterpart (sCD40L) are proteins that exhibit prothrombotic and proinflammatory properties on binding to their cell surface receptor CD40. The results of small clinical studies suggest that sCD40L levels could play a role in sepsis; however, there are no data on the association between sCD40L levels and mortality of septic patients. Thus, the aim of this study was to determine whether circulating sCD40L levels could be a marker of adverse outcome in a large cohort of patients with severe sepsis. METHODS: This was a multicenter, observational and prospective study carried out in six Spanish intensive care units. Serum levels of sCD40L, tumour necrosis factor-alpha and interleukin-10, and plasma levels of tissue factor were measured in 186 patients with severe sepsis at the time of diagnosis. Serum sCD40L was also measured in 50 age- and sex-matched controls. Survival at 30 days was used as the endpoint. RESULTS: Circulating sCD40L levels were significantly higher in septic patients than in controls (P = 0.01), and in non-survivors (n = 62) compared to survivors (n = 124) (P = 0.04). However, the levels of CD40L were not different regarding sepsis severity. Logistic regression analysis showed that sCD40L levels >3.5 ng/mL were associated with higher mortality at 30 days (odds ratio = 2.89; 95% confidence interval = 1.37 to 6.07; P = 0.005). The area under the curve of sCD40L levels >3.5 ng/mL as predictor of mortality at 30 days was 0.58 (95% CI = 0.51 to 0.65; P = 0.03). CONCLUSIONS: In conclusion, circulating sCD40L levels are increased in septic patients and are independently associated with mortality in these patients; thus, its modulation could represent an attractive therapeutic target

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

INTRODUCTION: Matrix metalloproteinases (MMPs) play a role in infectious diseases through extracellular matrix (ECM) degradation, which favors the migration of immune cells from the bloodstream to sites of inflammation. Although higher levels of MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) have been found in small series of patients with sepsis, MMP-10 levels have not been studied in this setting. The objective of this study was to determine the predictive value of MMP-9, MMP-10, and TIMP-1 on clinical severity and mortality in a large series of patients with severe sepsis. METHODS: This was a multicenter, observational, and prospective study carried out in six Spanish Intensive Care Units. We included 192 (125 surviving and 67 nonsurviving) patients with severe sepsis and 50 age- and sex-matched healthy controls in the study. Serum levels of MMP-9, MMP-10, TIMP-1, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-10 were measured in patients with severe sepsis at the time of diagnosis and in healthy controls. RESULTS: Sepsis patients had higher levels of MMP-10 and TIMP-1, higher MMP-10/TIMP-1 ratios, and lower MMP-9/TIMP-1 ratios than did healthy controls (P < 0.001). An association was found between MMP-9, MMP-10, TIMP-1, and MMP-9/TIMP-1 ratios and parameters of sepsis severity, assessed by the SOFA score, the APACHE-II score, lactic acid, platelet count, and markers of coagulopathy. Nonsurviving sepsis patients had lower levels of MMP-9 (P = 0.037), higher levels of TIMP-1 (P < 0.001), lower MMP-9/TIMP-1 ratio (P = 0.003), higher levels of IL-10 (P < 0.001), and lower TNF-alpha/IL-10 ratio than did surviving patients. An association was found between MMP-9, MMP-10, and TIMP-1 levels, and TNF-alpha and IL-10 levels. The risk of death in sepsis patients with TIMP-1 values greater than 531 ng/ml was 80% higher than that in patients with lower values (RR = 1.80; 95% CI = 1.13 to 2.87;P = 0.01; sensitivity = 0.73; specificity = 0.45). CONCLUSIONS: The novel findings of our study on patients with severe sepsis (to our knowledge, the largest series reporting data about MMP levels in sepsis) are that reduced MMP-9/TIMP-1 ratios and increased MMP-10 levels may be of great pathophysiologic significance in terms of severity and mortality, and that TIMP-1 levels may represent a biomarker to predict the clinical outcome of patients with sepsis

Low-cost inorganic cation exchange membrane for electrodialysis: optimum processing temperature for the cation exchanger

The optimum temperature for fixing zirconium phosphate, obtained by precipitation, on a low-cost ceramic support was determined in order to obtain an inorganic cation exchange membrane for electrodialysis. Zirconium phosphate ion exchange capacity maximised between 450 and 550°C, thus it was considered the optimum processing temperature. The origin of this maximum was investigated by means of X-ray diffraction and termogravimetry and evolved gas analysis. Zirconium phosphate formation by precipitation in the porous network of the support was verified by scanning electron microscopy and energy dispersive X-ray analysis and mercury intrusion porosimetry. The membrane obtained after thermal treatment at 450°C displayed selectivity to the cations present in the spent rinse water of the chromium plating process. This property allows the recovery of chromium by removing the cations through the cation exchange ceramic membrane.The authors wish to express their gratitude to the Spanish Ministry of Science and Innovation for the support given to the research study (National Basic Research Programme, Ref. CTQ2008-06750-C02-02), as well as for the FPU student grant awarded to one of the authors (Ref.: AP2009-4409).Mestre, S.; Sales, S.; Palacios, M.; Lorente, M.; Mallol, G.; Pérez-Herranz, V. (2013). Low-cost inorganic cation exchange membrane for electrodialysis: optimum processing temperature for the cation exchanger. Desalination and Water Treatment. 51(16-18):3317-3324. https://doi.org/10.1080/19443994.2012.749177S331733245116-18Strathmann, H. (2010). Electromembrane Processes: Basic Aspects and Applications. Comprehensive Membrane Science and Engineering, 391-429. doi:10.1016/b978-0-08-093250-7.00048-7Drioli, E., & Fontananova, E. (s. f.). Integrated Membrane Processes. Membrane Operations, 265-283. doi:10.1002/9783527626779.ch12Strathmann, H. (s. f.). Fundamentals in Electromembrane Separation Processes. Membrane Operations, 83-119. doi:10.1002/9783527626779.ch5Alberti, G., Casciola, M., Costantino, U., & Levi, G. (1978). Inorganic ion exchange membranes consisting of microcrystals of zirconium phosphate supported by Kynar®. Journal of Membrane Science, 3(2), 179-190. doi:10.1016/s0376-7388(00)83021-5Semiat, R., & Hasson, D. (s. f.). Seawater and Brackish-Water Desalination with Membrane Operations. Membrane Operations, 221-243. doi:10.1002/9783527626779.ch10Bregman, J. ., & Braman, R. . (1965). Inorganic ion exchange membranes. Journal of Colloid Science, 20(9), 913-922. doi:10.1016/0095-8522(65)90064-4Bishop, H. K., Bittles, J. A., & Guter, G. A. (1969). Investigation of inorganic ion exchange membranes for electrodialysis. Desalination, 6(3), 369-380. doi:10.1016/s0011-9164(00)80226-xRajan, K. S., Boies, D. B., Casolo, A. J., & Bregman, J. . (1966). Inorganic ion-exchange membranes and their application to electrodialysis. Desalination, 1(3), 231-246. doi:10.1016/s0011-9164(00)80255-6INAMUDDIN, KHAN, S., SIDDIQUI, W., & KHAN, A. (2007). Synthesis, characterization and ion-exchange properties of a new and novel ‘organic–inorganic’ hybrid cation-exchanger: Nylon-6,6, Zr(IV) phosphate. Talanta, 71(2), 841-847. doi:10.1016/j.talanta.2006.05.042HELEN, M., VISWANATHAN, B., & MURTHY, S. (2007). Synthesis and characterization of composite membranes based on α-zirconium phosphate and silicotungstic acid. Journal of Membrane Science, 292(1-2), 98-105. doi:10.1016/j.memsci.2007.01.018Yu.S. Dzyaz’ko, V.N. Belyakov, N.V. Stefanyak, S.L. Vasilyuk, Anion-exchange properties of composite ceramic membranes containing hydrated zirconium dioxide, Russ. J. Appl. Chem. 79 (2006) 769–773.Linkov, V. ., & Belyakov, V. . (2001). Novel ceramic membranes for electrodialysis. Separation and Purification Technology, 25(1-3), 57-63. doi:10.1016/s1383-5866(01)00090-9Linkov, V. M., Dzyaz’ko, Y. S., Belyakov, V. N., & Atamanyuk, V. Y. (2007). Inorganic composite membranes for electrodialytic desaltination. Russian Journal of Applied Chemistry, 80(4), 576-581. doi:10.1134/s1070427207040118El-Sourougy, M. R., Zaki, E. E., & Aly, H. F. (1997). Transport characteristics of ceramic supported zirconium phosphate membrane. Journal of Membrane Science, 126(1), 107-113. doi:10.1016/s0376-7388(96)00273-6Sánchez, E., Mestre, S., Pérez-Herranz, V., & García-Gabaldón, M. (2005). Síntesis de membranas cerámicas para la regeneración de baños de cromado agotados. Boletín de la Sociedad Española de Cerámica y Vidrio, 44(6), 409-414. doi:10.3989/cyv.2005.v44.i6.340Sánchez, E., Mestre, S., Pérez-Herranz, V., Reyes, H., & Añó, E. (2006). Membrane electrochemical reactor for continuous regeneration of spent chromium plating baths. Desalination, 200(1-3), 668-670. doi:10.1016/j.desal.2006.03.475Alberti, G., Casciola, M., Costantino, U., & Vivani, R. (1996). Layered and pillared metal(IV) phosphates and phosphonates. Advanced Materials, 8(4), 291-303. doi:10.1002/adma.19960080405Alberti, G., & Torracca, E. (1968). Crystalline insoluble salts of polybasic metals - II. Synthesis of crystalline zirconium or titanium phosphate by direct precipitation. Journal of Inorganic and Nuclear Chemistry, 30(1), 317-318. doi:10.1016/0022-1902(68)80096-xTrobajo, C., Khainakov, S. A., Espina, A., & García, J. R. (2000). On the Synthesis of α-Zirconium Phosphate. Chemistry of Materials, 12(6), 1787-1790. doi:10.1021/cm0010093Alberti, G. (1978). Syntheses, crystalline structure, and ion-exchange properties of insoluble acid salts of tetravalent metals and their salt forms. Accounts of Chemical Research, 11(4), 163-170. doi:10.1021/ar50124a007Rajeh, A. O., & szirtes, L. (1995). Investigations of crystalline structure of gamma-zirconium phosphate. Journal of Radioanalytical and Nuclear Chemistry Articles, 196(2), 319-322. doi:10.1007/bf02038050Krogh Andersen, A. M., Norby, P., Hanson, J. C., & Vogt, T. (1998). Preparation and Characterization of a New 3-Dimensional Zirconium Hydrogen Phosphate, τ-Zr(HPO4)2. Determination of the Complete Crystal Structure Combining Synchrotron X-ray Single-Crystal Diffraction and Neutron Powder Diffraction. Inorganic Chemistry, 37(5), 876-881. doi:10.1021/ic971060hFeng, Y., He, W., Zhang, X., Jia, X., & Zhao, H. (2007). The preparation of nanoparticle zirconium phosphate. Materials Letters, 61(14-15), 3258-3261. doi:10.1016/j.matlet.2006.11.132Clearfield, A. (2000). INORGANIC ION EXCHANGERS, PAST, PRESENT, AND FUTURE. Solvent Extraction and Ion Exchange, 18(4), 655-678. doi:10.1080/07366290008934702Szirtes, L., Shakshooki, S. K., Szeleczky, A. M., & Rajeh, A. O. (1998). Thermoanalyncal Investigation of Some Layered Zirconium Salts and Their Various Derivatives I. Journal of Thermal Analysis and Calorimetry, 51(2), 503-515. doi:10.1007/bf03340188Al-Othman, A., Tremblay, A. Y., Pell, W., Letaief, S., Burchell, T. J., Peppley, B. A., & Ternan, M. (2010). Zirconium phosphate as the proton conducting material in direct hydrocarbon polymer electrolyte membrane fuel cells operating above the boiling point of water. Journal of Power Sources, 195(9), 2520-2525. doi:10.1016/j.jpowsour.2009.11.052Thakkar, R., Patel, H., & Chudasama, U. (2007). A comparative study of proton transport properties of zirconium phosphate and its metal exchanged phases. Bulletin of Materials Science, 30(3), 205-209. doi:10.1007/s12034-007-0036-3Jiang, P., Pan, B., Pan, B., Zhang, W., & Zhang, Q. (2008). A comparative study on lead sorption by amorphous and crystalline zirconium phosphates. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 322(1-3), 108-112. doi:10.1016/j.colsurfa.2008.02.035García-Gabaldón, M., Pérez-Herranz, V., García-Antón, J., & Guiñón, J. L. (2009). Use of ion-exchange membranes for the removal of tin from spent activating solutions. Desalination and Water Treatment, 3(1-3), 150-156. doi:10.5004/dwt.2009.453García-Gabaldón, M., Pérez-Herranz, V., García-Antón, J., & Guiñón, J. L. (2009). Effect of hydrochloric acid on the transport properties of tin through ion-exchange membranes. Desalination and Water Treatment, 10(1-3), 73-79. doi:10.5004/dwt.2009.69

Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio

OBJECTIVE: Higher circulating levels of tissue inhibitor of matrix metalloproteinases (TIMP)-1 at the time of severe sepsis diagnosis have been reported in nonsurviving than in surviving patients. However, the following questions remain unanswered: 1) Does TIMP-1/MMP-9 ratio differ throughout the first week of intensive care between surviving and non-surviving patients? 2) Is there an association between TIMP-1/MMP-9 ratio and sepsis severity and mortality during such period? 3) Could TIMP-1/MMP-9 ratio during the first week be used as an early biomarker of sepsis outcome? 4) Is there an association between TIMP-1/MMP-9 ratio and coagulation state and circulating cytokine levels during the first week of intensive care in these patients? The present study sought to answer these questions. METHODS: Multicenter, observational and prospective study carried out in six Spanish Intensive Care Units (ICUs) of 295 patients with severe sepsis. Were measured circulating levels of TIMP-1, MMP-9, tumour necrosis factor (TNF)-alpha, interleukin (IL)-10 and plasminogen activator inhibitor (PAI)-1 at day 1, 4 and 8. End-point was 30-day mortality. RESULTS: We found higher TIMP-1/MMP-9 ratio during the first week in non-surviving (n = 98) than in surviving patients (n = 197) (p<0.01). Logistic regression analyses showed that TIMP-1/MMP-9 ratio at days 1, 4 and 8 was associated with mortality. Receiver operating characteristic (ROC) curves showed that TIMP-1/MMP-9 ratio at days 1, 4 and 8 could predict mortality. There was an association between TIMP-1/MMP-9 ratio and TNF-alpha, IL-10, PAI-1 and lactic acid levels, SOFA score and platelet count at days 1, 4 and 8. CONCLUSIONS: The novel findings of our study were that non-surviving septic patients showed persistently higher TIMP-1/MMP-9 ratio than survivors ones during the first week, which was associated with severity, coagulation state, circulating cytokine levels and mortality; thus representing a new biomarker of sepsis outcome